Okairos - is a non-listed clinical-stage biopharmaceutical company, developing genetic vaccines for major infectious diseases - including malaria, hepatitis C, HIV, respiratory syncytial virus and cancer - using a novel proprietary technology. The company is also pursuing therapeutic vaccines to treat cancer.
Okairos AG was acquired by GlaxoSmithKline on May 29, 2013.
Join Mergr to view all 177 acquisitions of life science companies in 2013, including 20 acquisitions by private equity firms, and 157 by strategics.
Out of 60 sectors in the Mergr database, life science ranked 10 in number of deals in 2013. The largest life science acquisition in 2013 was Onyx Pharmaceuticals - which was acquired by Amgen for $10.4B.
Join Mergr to view this profile - and discover more life science acquisitions of companies like Okairos AG.
No obligation. Cancel anytime.